<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00849537</url>
  </required_header>
  <id_info>
    <org_study_id>8711</org_study_id>
    <nct_id>NCT00849537</nct_id>
  </id_info>
  <brief_title>The Effect of Intravitral Injection of Triamcinolone Combined With Cataract Surgery (Phacoemulsification) on Diabetic Macular Edema and Diabetic Retinopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      In this study, regressed proliferative diabetic retinopathy, very severe, severe and moderate
      non-prolifrative diabetic retinopathy patients who were going to have a cataract surgery,
      underwent a complete eye examination, OCT, FAG and color photography 2 weeks prior to their
      operation. All patients divided in two: 1) control group (Phyco,PCIOL), 2) triamcinolone
      treatment group (Phaco with PCIOL+IVT). One month after surgery a complete eye examination
      will be done especially; IOP and endophthalmitis. A 6 month follow-up will be done for these
      two groups and diabetic retinopathy progression will be checked.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">April 2009</completion_date>
  <primary_completion_date type="Anticipated">April 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Macula diameter</measure>
    <time_frame>6th week, 3, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetic retinopathy</measure>
    <time_frame>6th weeks, 3 and 6 months later</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Triamcinolone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of intravitreal Triamcinolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Injection of intravitreal Triamcinolone</description>
    <arm_group_label>Triamcinolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients with non-proliferative diabetic retinopathy and regressed PDR

        Exclusion Criteria:

          -  Uncontrolled HTN

          -  History of glaucoma

          -  Active PDR

          -  NVI

          -  TRD

          -  Any ophthalmic operation

          -  Renal problem(cr&gt;3)

          -  CVA

          -  Uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Siamak Moradian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaheed Beheshti University Of Medical Science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Siamak Moradian, MD</last_name>
    <phone>00982122592200</phone>
    <email>Moradian33195@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ophthalmic Research Centre</name>
      <address>
        <city>Tehran</city>
        <zip>1666663111</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Siamak Moradian,MD</name>
      <address>
        <city>Tehran</city>
        <zip>166666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2009</study_first_posted>
  <last_update_submitted>February 23, 2009</last_update_submitted>
  <last_update_submitted_qc>February 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2009</last_update_posted>
  <responsible_party>
    <organization>Shaheed Beheshti Medical University</organization>
  </responsible_party>
  <keyword>Triamcinolon</keyword>
  <keyword>Cataract</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>non-proliferative retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

